Labcorp Holdings Inc. (NYSE:LH) Stock Has Consensus Price Target of $369.08

Labcorp logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts rate Labcorp a Moderate Buy: Eight of 12 analysts recommend buying, three say hold, and one rates it a strong buy. The average one-year price target is $369.08.
  • Quarterly results exceeded expectations: Labcorp reported EPS of $4.78 versus the $4.64 consensus and revenue of $3.81 billion, up 6.9% year over year.
  • The company declared a quarterly dividend of $0.72 per share, equivalent to $2.88 annually and a yield of about 0.8%.
  • Interested in Labcorp? Here are five stocks we like better.

Labcorp Holdings Inc. (NYSE:LH - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twelve research firms that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $369.08.

A number of research analysts have recently commented on the company. Truist Financial upped their price target on Labcorp from $365.00 to $395.00 and gave the company a "buy" rating in a research report on Thursday, October 29th. Piper Sandler raised their price target on Labcorp from $300.00 to $309.00 and gave the company a "neutral" rating in a report on Tuesday, August 4th. Barclays raised their price target on Labcorp from $330.00 to $380.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 28th. Morgan Stanley reissued an "overweight" rating and set a $388.00 price objective on shares of Labcorp in a research note on Thursday, October 29th. Finally, Robert W. Baird upped their price target on Labcorp from $361.00 to $396.00 and gave the company an "outperform" rating in a research report on Thursday, October 29th.

View Our Latest Stock Analysis on Labcorp

Labcorp Stock Performance

NYSE:LH opened at $369.36 on Friday. Labcorp has a fifty-two week low of $245.00 and a fifty-two week high of $375.10. The company has a 50 day simple moving average of $333.61 and a two-hundred day simple moving average of $294.59. The company has a market capitalization of $29.99 billion, a PE ratio of 30.30, a P/E/G ratio of 2.09 and a beta of 0.86. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.22 and a current ratio of 1.41.

Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings data on Wednesday, October 28th. The medical research company reported $4.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.64 by $0.14. The company had revenue of $3.81 billion for the quarter, compared to analysts' expectations of $3.76 billion. Labcorp had a net margin of 6.88% and a return on equity of 17.13%. The business's revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.18 EPS. Research analysts anticipate that Labcorp will post 18.51 earnings per share for the current year.

Labcorp Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Tuesday, November 24th. Labcorp's dividend payout ratio is presently 23.63%.

Insider Activity at Labcorp

In other news, EVP Brian J. Caveney sold 2,000 shares of the company's stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $372.04, for a total value of $744,080.00. Following the completion of the transaction, the executive vice president owned 34,562 shares of the company's stock, valued at $12,858,446.48. This represents a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Richelle P. Parham sold 1,078 shares of Labcorp stock in a transaction on Friday, October 30th. The shares were sold at an average price of $361.22, for a total transaction of $389,395.16. Following the completion of the sale, the director owned 2,288 shares in the company, valued at approximately $826,471.36. This represents a 32.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 3,749 shares of company stock worth $1,377,699. Company insiders own 0.84% of the company's stock.

Hedge Funds Weigh In On Labcorp

Hedge funds have recently added to or reduced their stakes in the company. Carolina Financial Advisors Inc raised its holdings in shares of Labcorp by 2.1% in the 3rd quarter. Carolina Financial Advisors Inc now owns 1,374 shares of the medical research company's stock valued at $423,000 after purchasing an additional 28 shares in the last quarter. Kestra Advisory Services LLC boosted its position in shares of Labcorp by 6.3% in the 3rd quarter. Kestra Advisory Services LLC now owns 6,253 shares of the medical research company's stock worth $1,927,000 after purchasing an additional 373 shares in the last quarter. Advisors Asset Management Inc. purchased a new stake in shares of Labcorp during the third quarter worth about $1,840,000. Innovator Capital Management LLC acquired a new position in Labcorp during the 3rd quarter valued at approximately $1,388,000. Finally, Zacks Investment Management grew its stake in Labcorp by 4.2% during the 3rd quarter. Zacks Investment Management now owns 89,168 shares of the medical research company's stock valued at $27,474,000 after purchasing an additional 3,600 shares during the last quarter. 95.94% of the stock is currently owned by institutional investors.

Labcorp Company Profile

(Get Free Report)

Labcorp NYSE: LH, formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.

See Also

Analyst Recommendations for Labcorp (NYSE:LH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Labcorp Right Now?

Before you consider Labcorp, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Labcorp wasn't on the list.

While Labcorp currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines